JP2022541749A - 治療薬としての細胞毒素のペプチドコンジュゲート - Google Patents

治療薬としての細胞毒素のペプチドコンジュゲート Download PDF

Info

Publication number
JP2022541749A
JP2022541749A JP2022501188A JP2022501188A JP2022541749A JP 2022541749 A JP2022541749 A JP 2022541749A JP 2022501188 A JP2022501188 A JP 2022501188A JP 2022501188 A JP2022501188 A JP 2022501188A JP 2022541749 A JP2022541749 A JP 2022541749A
Authority
JP
Japan
Prior art keywords
nrc1rd1
nrc1c
ora1
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022501188A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021007435A5 (US07847105-20101207-C00016.png
Inventor
リチャード マーシャル，ダニエル
マリー チェンゲリー，ヨハンナ
ジョン マグワイア，ロバート
エイ ボークマン，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybrexa 2 Inc
Original Assignee
Cybrexa 2 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 2 Inc filed Critical Cybrexa 2 Inc
Publication of JP2022541749A publication Critical patent/JP2022541749A/ja
Publication of JPWO2021007435A5 publication Critical patent/JPWO2021007435A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022501188A 2019-07-10 2020-07-09 治療薬としての細胞毒素のペプチドコンジュゲート Pending JP2022541749A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962872643P 2019-07-10 2019-07-10
US62/872,643 2019-07-10
US202063040859P 2020-06-18 2020-06-18
US63/040,859 2020-06-18
PCT/US2020/041411 WO2021007435A1 (en) 2019-07-10 2020-07-09 Peptide conjugates of cytotoxins as therapeutics

Publications (2)

Publication Number Publication Date
JP2022541749A true JP2022541749A (ja) 2022-09-27
JPWO2021007435A5 JPWO2021007435A5 (US07847105-20101207-C00016.png) 2023-07-18

Family

ID=71787212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501188A Pending JP2022541749A (ja) 2019-07-10 2020-07-09 治療薬としての細胞毒素のペプチドコンジュゲート

Country Status (17)

Country Link
US (2) US11634508B2 (US07847105-20101207-C00016.png)
EP (1) EP3997093A1 (US07847105-20101207-C00016.png)
JP (1) JP2022541749A (US07847105-20101207-C00016.png)
KR (1) KR20220052918A (US07847105-20101207-C00016.png)
CN (1) CN114341162A (US07847105-20101207-C00016.png)
AU (1) AU2020309570A1 (US07847105-20101207-C00016.png)
BR (1) BR112022000337A2 (US07847105-20101207-C00016.png)
CA (1) CA3146560A1 (US07847105-20101207-C00016.png)
CL (1) CL2022000038A1 (US07847105-20101207-C00016.png)
CO (1) CO2022001316A2 (US07847105-20101207-C00016.png)
CR (1) CR20220058A (US07847105-20101207-C00016.png)
EC (1) ECSP22010228A (US07847105-20101207-C00016.png)
IL (1) IL289658A (US07847105-20101207-C00016.png)
MX (1) MX2022000449A (US07847105-20101207-C00016.png)
PE (1) PE20220563A1 (US07847105-20101207-C00016.png)
TW (1) TW202116778A (US07847105-20101207-C00016.png)
WO (1) WO2021007435A1 (US07847105-20101207-C00016.png)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114302744A (zh) 2019-07-10 2022-04-08 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物
CN116199739A (zh) * 2020-09-30 2023-06-02 映恩生物制药（苏州）有限公司 一种抗肿瘤化合物及其制备方法和应用
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
CN117897175A (zh) 2021-04-29 2024-04-16 美商斯布雷克萨二号公司 拓扑异构酶i抑制剂的肽缀合物的给药方案
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
US20230416331A1 (en) * 2021-11-17 2023-12-28 Cybrexa 4, Inc. Peptide conjugates of peptidic tubulin inhibitors as therapeutics
WO2023174401A1 (zh) * 2022-03-18 2023-09-21 映恩生物制药（苏州）有限公司 Gpc3抗体药物偶联物及其用途
WO2023191209A1 (ko) * 2022-03-29 2023-10-05 주식회사 퓨전바이오텍 친수성 펩타이드를 포함하는 마이셀 및 이의 용도

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637770A (en) 1991-01-16 1997-06-10 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
PT841924E (pt) 1995-08-02 2003-02-28 Univ Newcastle Ventures Ltd Compostos de benzimidazolo
WO1997041124A1 (fr) 1996-04-26 1997-11-06 Daiichi Pharmaceutical Co., Ltd. Procede pour la preparation de tetrahydroindolizines
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
IN189180B (US07847105-20101207-C00016.png) 1997-07-09 2003-01-04 Chong Kun Dang Corp
CN1250293C (zh) 1998-05-22 2006-04-12 第一制药株式会社 药物复合物
BR9915198A (pt) 1998-10-30 2001-08-14 Daiichi Seiyaku Co Composto dds e método para medição do mesmo
PL347500A1 (en) 1998-11-03 2002-04-08 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
MXPA01007001A (es) 1999-01-11 2002-07-30 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas.
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
CA2396513A1 (en) 1999-12-13 2001-06-14 Yanzhi Zhang Pseudomycin phosphate prodrugs
EP1308171A1 (en) 2000-07-13 2003-05-07 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DK1487493T3 (da) 2002-03-01 2010-05-25 Univ Tulane Konjugater af cytotoksiske midler og biologisk aktive peptider
UA77296C2 (en) 2002-03-20 2006-11-15 Bristol Myers Squibb Co Phosphate prodrugs of fluoro-oxindols
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
CN102940889A (zh) 2003-05-14 2013-02-27 伊缪诺金公司 药物缀合物组合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
SI1651162T1 (sl) 2003-05-20 2016-02-29 Immunogen, Inc. Izboljšani citotoksični agenti, ki vsebujejo nove majtanzinoide
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101138471B1 (ko) 2003-07-25 2012-04-25 화이자 인코포레이티드 트리시클로 ｐａｒｐ 저해제
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
JP5545690B2 (ja) 2003-12-01 2014-07-09 クドス ファーマシューティカルズ リミテッド 癌治療のためのｄｎａ損傷修復阻害剤
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
WO2006033007A2 (en) 2004-09-22 2006-03-30 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
AU2005286190A1 (en) 2004-09-22 2006-03-30 Cancer Research Technology Ltd. Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
EP1794163B1 (en) 2004-09-22 2009-12-23 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
US20060182750A1 (en) 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
EA200702239A1 (ru) 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
CA2620343C (en) 2005-08-24 2013-01-08 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
CA2623822C (en) 2005-09-29 2013-11-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
JP5117390B2 (ja) 2005-11-08 2013-01-16 イミュノジェン・インコーポレーテッド メイタンシノールの調製法
EP2329818A1 (en) 2006-01-17 2011-06-08 Abbott Laboratories Combination therapy with PARP inhibitors
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
AU2008268432B2 (en) * 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
PL2187965T3 (pl) * 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
KR20100137585A (ko) 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 강력한 복합체 및 친수성 링커
TR201907573T4 (tr) 2009-06-03 2019-06-21 Immunogen Inc Konjugasyon yöntemleri̇
WO2011066418A1 (en) 2009-11-25 2011-06-03 Academia Sinica The tumor-selective anti-cancer prodrug bqc-g
KR102108226B1 (ko) 2010-02-12 2020-05-08 화이자 인코포레이티드 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체
US20120322741A1 (en) * 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP4098272A3 (en) 2010-07-13 2023-03-08 University of Rhode Island Board of Trustees Compositions comprising a ph-sensitive membrane insertion polipeptide
CA2808313C (en) 2010-08-13 2021-04-13 Rhode Island Board Of Governors For Higher Education Liposomes comprising ph low insertion peptide (phlip) polypeptides
CA2816681A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
US9180203B2 (en) * 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
WO2014093343A2 (en) 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
US9999680B2 (en) 2013-02-28 2018-06-19 Immunogen, Inc. Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
WO2015108986A1 (en) 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
KR102351755B1 (ko) 2014-04-10 2022-01-14 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
CN106794185A (zh) 2014-08-22 2017-05-31 克洛维斯肿瘤有限公司 Rucaparib的高剂量强度片剂
CN106470697B (zh) 2014-09-16 2019-10-25 兴盟生物医药(苏州)有限公司 抗egfr抗体以及其用途
KR20170088905A (ko) 2014-11-19 2017-08-02 이뮤노젠 아이엔씨 세포 결합 작용제-세포독성 작용제 접합체를 제조하기 위한 공정
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MX2018006282A (es) 2015-11-24 2019-01-21 Theravance Biopharma R&D Ip Llc Profarmacos de un compuesto inhibidor de jak para el tratamiento de la enfermedad inflamatoria gastrointestinal.
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
EP3426301A4 (en) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
WO2017180834A1 (en) * 2016-04-13 2017-10-19 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
WO2017210608A1 (en) 2016-06-02 2017-12-07 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
EP3491007A4 (en) 2016-07-29 2020-04-22 Memorial Sloan-Kettering Cancer Center RADIO-MARKED LIGANDS FOR TARGETED PET / SPECT IMAGING AND METHODS OF USE THEREOF
MX2019001905A (es) 2016-08-16 2019-05-15 Aist Peptido objetivo de tumor maligno.
US11738096B2 (en) 2016-09-22 2023-08-29 Yale University Method of detecting diseased or damaged tissue with a pH-triggered polypeptide fluorophore composition
EP3634498A4 (en) 2017-06-09 2021-08-25 Rhode Island Council on Postsecondary Education CONNECTED AND OTHER PH-RIGIDED CONNECTIONS
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
WO2019136298A1 (en) 2018-01-05 2019-07-11 Cybrexa, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2019140271A2 (en) 2018-01-12 2019-07-18 Prolynx Llc Synergistic cancer treatment
JP2021524740A (ja) 2018-05-18 2021-09-16 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
US20200237926A1 (en) 2019-01-28 2020-07-30 Rhode Island Council On Postsecondary Education pHLIP® targeted delivery of potent cytotoxic compounds
KR102498681B1 (ko) 2019-03-29 2023-02-09 메디뮨 리미티드 화합물 및 이의 접합체
CN114302744A (zh) 2019-07-10 2022-04-08 赛博克萨3公司 作为治疗剂的微管靶向剂的肽缀合物

Also Published As

Publication number Publication date
MX2022000449A (es) 2022-04-25
KR20220052918A (ko) 2022-04-28
PE20220563A1 (es) 2022-04-13
ECSP22010228A (es) 2022-05-31
CO2022001316A2 (es) 2022-05-10
IL289658A (en) 2022-03-01
AU2020309570A1 (en) 2022-02-03
US20210009719A1 (en) 2021-01-14
CA3146560A1 (en) 2021-01-14
BR112022000337A2 (pt) 2022-04-12
CR20220058A (es) 2022-07-19
CL2022000038A1 (es) 2022-08-19
WO2021007435A1 (en) 2021-01-14
US11634508B2 (en) 2023-04-25
TW202116778A (zh) 2021-05-01
CN114341162A (zh) 2022-04-12
EP3997093A1 (en) 2022-05-18
US20240010755A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
JP2022541749A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
JP7356450B2 (ja) 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法
JP7447002B2 (ja) ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤
EP3856345A1 (en) Process of manufacture of a compound for inhibiting the activity of shp2
JP2021008500A (ja) Ｓｔｉｎｇ作動化合物
US20240067616A1 (en) Peptide conjugates of microtubule-targeting agents as therapeutics
JPWO2021007435A5 (US07847105-20101207-C00016.png)
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
WO2022155172A1 (en) Peptide conjugates of therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611